Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial
The Lancet Infectious Diseases, 06/29/2012
Kuhn L et al. – Viral–load testing through 52 weeks can identify all children likely to fail this protease–inhibitor–switch strategy. Switching children once suppressed to a nevirapine–based regimen might be a valuable treatment option if adequate viral–load monitoring can be done.